428 related articles for article (PubMed ID: 30477151)
1. Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari C; Marisi G; Passardi A; Matteucci L; De Maio G; Ulivi P
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477151
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy challenge and hope in colorectal cancer.
Burz C; Rosca A; Pop VV; Buiga R; Aldea C; Samasca G; Silaghi C; Sur D; Lupan I; Pricopie A
Expert Rev Mol Diagn; 2019 Apr; 19(4):341-348. PubMed ID: 30943811
[TBL] [Abstract][Full Text] [Related]
3. From tumour heterogeneity to advances in precision treatment of colorectal cancer.
Punt CJ; Koopman M; Vermeulen L
Nat Rev Clin Oncol; 2017 Apr; 14(4):235-246. PubMed ID: 27922044
[TBL] [Abstract][Full Text] [Related]
4. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
Rebersek M
Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
[TBL] [Abstract][Full Text] [Related]
5. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
6. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
[TBL] [Abstract][Full Text] [Related]
7. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
[TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
9. Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.
Kasprzak A; Adamek A
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31623387
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer.
Ding Y; Li W; Wang K; Xu C; Hao M; Ding L
Biomed Res Int; 2020; 2020():6843180. PubMed ID: 32258135
[TBL] [Abstract][Full Text] [Related]
11. Novel Diagnostic Biomarkers in Colorectal Cancer.
Zygulska AL; Pierzchalski P
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055034
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.
Gargalionis AN; Papavassiliou AG
Trends Cancer; 2017 Mar; 3(3):166-168. PubMed ID: 28718430
[TBL] [Abstract][Full Text] [Related]
13. Current and future biomarkers in the treatment of colorectal cancer.
Cuyle PJ; Prenen H
Acta Clin Belg; 2017 Apr; 72(2):103-115. PubMed ID: 27917697
[TBL] [Abstract][Full Text] [Related]
14. Proteome Heterogeneity in Colorectal Cancer.
Lim LC; Lim YM
Proteomics; 2018 Feb; 18(3-4):. PubMed ID: 29316255
[TBL] [Abstract][Full Text] [Related]
15. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
19. Role of circulating tumor DNA in the management of patients with colorectal cancer.
Moati E; Taly V; Didelot A; Perkins G; Blons H; Taieb J; Laurent-Puig P; Zaanan A
Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):396-402. PubMed ID: 29627453
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis.
Miyake M; Takemasa I; Matoba R; Tanino M; Niijima S; Ikeda M; Yamamoto H; Sekimoto M; Kuhara S; Okayama T; Monden M; Matsubara K; Mori M
Int J Oncol; 2011 Oct; 39(4):781-9. PubMed ID: 21701771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
